Clinical effectiveness of vedolizumab used in the treatment of Crohn's disease within the Drug Program.
PROSPECTIVE, OBSERVATIONAL STUDY TAKING INTO ACCOUNT FATIGUE AND OTHER SYMPTOMS REPORTED BY PATIENTS
We invite you to participate in a multicenter observational study entitled "Clinical effectiveness of vedolizumab used in the treatment of Crohn's disease within the Drug Program".
Vedolizumab in Poland is still a relatively new drug, available only within the Drug Program. Due to the Drug Program - the use of vedolizumab in patients with Crohn's disease - there is a justified need to characterize the population of patients qualifying for it and to assess the effectiveness of such therapy in the conditions of medical practice shaped by the Drug Program. Therefore, data collected during the study will allow to obtain an answer to these needs, which is why your active involvement is so important.
To start the study, it is necessary to sign an online contract, so please register and follow the instructions that appear on the computer screen.
After successful registration and signing of the electronic contract, please log in with the data obtained during the account creation process.
BioStat® is responsible for analyzing the material and ensuring
the smooth course of the study.
If you have any questions, please contact the study organizer at:
BioStat Sp. z o.o.
ul. Kowalczyka 17, 44-206 Rybnik
tel: 666 069 814; email: [email protected]
B.32 Drug Program.
Takeda Pharma sp. z o.o.
68 Prosta Street, 00-838 Warsaw
tel: +48 22 608 13 00/01
fax: +48 22 608 13 03